Skip to main content
Clinical Trials/ACTRN12621000094875
ACTRN12621000094875
Not yet recruiting
未知

Growth, body composition and developmental assessment of children conceived following a lipiodol hysterosalpingogram

niversity of Auckland, office of research strategy and integrity0 sites100 target enrollmentFebruary 1, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Cognitive development
Sponsor
niversity of Auckland, office of research strategy and integrity
Enrollment
100
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 1, 2021
End Date
TBD
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
niversity of Auckland, office of research strategy and integrity

Eligibility Criteria

Inclusion Criteria

  • Exposure group: Children who are aged between 6\-14 years, and have been conceived within 6 months of their mother receiving lipiodol hysterosalpingogram (HSG).
  • Control group: children who are aged between 6\-14 years and are siblings of a child in the exposure group. They have been conceived without any assisted reproductive technology.

Exclusion Criteria

  • Overt, pre\-existing developmental delay.
  • Chronic illness that can impact on developmental assessment.
  • Medication known to affect neurocognitive outcome such as anti\-depressives, methylphenidate etc.
  • A history of recreational drug use including tobacco and alcohol.
  • Known bone fragility disorders or medical conditions that could affect bone density.
  • Twins conceived following lipiodol.

Outcomes

Primary Outcomes

Not specified

Similar Trials